Skip to main content

Evonik, Genedata Extend Software, Services Agreement

NEW YORK (GenomeWeb News) – Evonik, a specialty chemicals firm, has extended an existing collaboration with Genedata allowing it to continue to use Genedata Selector, the company's software for managing and analyzing strain information, and in addition, to take advantage of Genedata's consulting and specialized IT services.

Evonik has been using the Selector software to manage, visualize, and analyze genomic data from production strains in order to identify mutations and explore complex genotype-phenotype relationships. These strains are used to produce bio-based chemicals, nutritional proteins, food and feed additives, and cosmetics ingredients.

Under the new agreement, Evonik will now also use Genedata's data analysis consulting such as proprietary genome annotations, production strain comparisons, cellular signaling network reconstructions for proprietary strains, and statistical expression analysis reports. Evonik will also have access to IT services such as hosting and remote server maintenance, software and database integration services, and data migration and integration services.

According to Genedata, these services will help Evonik eliminate resource bottlenecks, provide cost-effective support for projects, and deliver results quickly and efficiently.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.